Cartesian Therapeutics Files Proxy Statement
Ticker: RNAC · Form: DEFA14A · Filed: Apr 28, 2025 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | DEFA14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, corporate-governance
TL;DR
Cartesian Therapeutics (formerly Selecta Biosciences) filed its proxy statement on 4/28/25. Standard shareholder meeting stuff.
AI Summary
Cartesian Therapeutics, Inc. filed a Definitive Proxy Statement (DEFA14A) on April 28, 2025. This filing is related to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company was formerly known as Selecta Biosciences Inc. before a name change on January 9, 2009.
Why It Matters
This filing is a standard regulatory requirement for public companies to communicate with shareholders regarding important corporate decisions and upcoming meetings.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently indicate new risks or changes in the company's financial or operational status.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- Selecta Biosciences Inc. (company) — Former company name
- 20250428 (date) — Filing date
- 20090109 (date) — Date of former company name change
FAQ
What type of filing is this DEFA14A for Cartesian Therapeutics, Inc.?
This is a Definitive Proxy Statement (DEFA14A) filed pursuant to Section 14(a) of the Securities Exchange Act of 1934.
When was this DEFA14A filing made?
The filing was made on April 28, 2025.
What was Cartesian Therapeutics, Inc. formerly known as?
The company was formerly known as Selecta Biosciences Inc.
When did the company change its name from Selecta Biosciences Inc.?
The date of the name change was January 9, 2009.
What is the primary purpose of a DEFA14A filing?
A DEFA14A filing provides information required in a proxy statement, which is used to solicit proxies from shareholders for an upcoming meeting.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 28, 2025 regarding Cartesian Therapeutics, Inc. (RNAC).